Advances in Urothelial Cancer

Dear Colleagues,

Recent advances in genomics technologies have classified molecular subtypes of bladder cancer based on gene expression profiling and have examined their significance in clinical utility to inform prognosis and/or to predict therapeutic responses.

The use of immune checkpoint inhibitors, particularly with antibodies directed against programmed cell death 1 protein (PD-1) or its ligand (PD-L1), has led to important advances in the treatment of metastatic urothelial cancer and been tested in the early stages of bladder cancer. However, only a small number of patients respond to checkpoint inhibitors. Therefore, attempts are being made to develop biomarkers that could help to identify urothelial cancer patients who are likely to respond to these drugs.

As a type of targeted therapy, therapeutic agents such as enfortumab vedotin, an antibody-drug conjugate designed to treat Nectin-4 expressing cancer, and erdafitinib, a small molecule inhibitor of fibroblast growth factor receptor, have been accepted in clinical studies on metastatic bladder cancer.

Additionally, many combinations of therapies are being tested for urothelial cancer, combining either multiple immunotherapy drugs or immunotherapy drugs with other types of treatment. These advances offer patients better monitoring opportunities, unique treatment options, and greater hope for long-term survival.

In this Special Issue on “Advances in the Urothelial Cancer”, we will include the information and available data regarding molecular classification, diagnosis, immunotherapy, various targeted agents, and antibody-drug conjugates that have recently shown promising results against urothelial cancer.

Dr. Ho Kyung Seo
Dr. Eu Chang Hwang
Dr. Whi-An Kwon
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.